Traneta M 850 

Presentation:Traneta M 850 Tablet, available in Bangladesh, is a combination tablet containing Linagliptin 2.5 mgand Metformin Hydrochloride BP 850 mg.

Indications:Traneta M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellituswhentreatment with both linagliptin and metformin is appropriate.  

Dosage and Administration:The dosageof Traneta M should be individualized based on the patient's current treatment regimen, glycemic control, and tolerability, using the lowest effective dose. The usual starting dose depends on the patient's prior antidiabetic treatment.

• Patients not currently treated with metformin: The usual starting dose is linagliptin 2.5 mg/metformin 500 mg twice daily or linagliptin 2.5 mg/metformin 850 mg once daily with meals.
• Patients already treated with metformin: May be switched to Traneta M containing the same total daily dose of metformin and the appropriate dose of linagliptin (2.5 mg twice daily).
• The maximum recommended daily dose of linagliptin is 5 mg, and the maximum recommended daily dose of metformin is 2550 mg. Traneta M 850 is typically administered once or twice daily with mealsto reduce gastrointestinal side effects associated with metformin.The tablet should be swallowed whole and not crushed, split, or chewed.  

Side Effects:Common side effects associated with metformin include gastrointestinal disturbances such as diarrhea, nausea, vomiting, abdominal pain, and flatulence, particularly during initiation of therapy.These effects are often transient. Hypoglycemia is not usually seen with metformin monotherapy but can occur when Traneta M is used in combination with insulin secretagogues (e.g., sulfonylureas).Side effects potentially related to linagliptin include upper respiratory tract infection, nasopharyngitis, and headache.Pancreatitis has been reported in some patients receiving linagliptin.  

Precautions:Traneta M is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis (including diabetic ketoacidosis), or a history of serious hypersensitivity reaction to linagliptin or metformin.It is not recommended for use in patients with type 1 diabetes. Caution should be exercised in patients with moderate renal impairment, heart failure, liver disease, and excessive alcohol intake due to the risk of lactic acidosis associated with metformin. Renal function should be assessed prior to initiation of therapy and periodically thereafter. Discontinue Traneta M if pancreatitis is suspected.

Storage:Store Traneta M 850 tablets in a cool (below 30°C) and dry place, protected from light and moisture.Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.